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1.1. Clinical Aspect
Large volume bony defects resulting from traumatic incidents, con-
genital abnormalities, infection, or cancer resections represent a great
challenge for orthopedic, craniomaxillofacial, and reconstructive sur-
geons. Ideally, functional reconstruction of bone defects requires the
available bone grafts to possess mechanical strength, microstructure,
and function as similar to native bone tissue as possible. This allows
full integration with the neighboring host bone and, importantly, the
performance of the functions of native bone tissue. Thus, an ideal func-
tional bone graft should possess the following characteristics: high
osteoinductive and angiogenic potentials, biological safety, low donor-
site morbidity, no size restrictions, readily accessible to surgeons, long
shelf life, and reasonable cost. Although numerous strategies have
been used for bone defect reconstruction, none of the currently avail-
able bone substitutes have all of the ideal characteristics.
1.2. Current Approaches for Large Bone Defect Treatment
The currently available approaches for bone defect reconstruction,
including bone transport methods, biomaterial implantation, and bone
grafting, all have speciﬁc indications and limitations. According to the
requirements of functional bone defect reconstruction, autologous
bone grafting is the gold standard for large bone defect treatment be-
cause this graft contains the cell types, matrix, and vasculature necessary
for proper bone regrowth in the injured area. However, the difﬁculties
associated with these grafts such as additional host morbidity, donor
site shortages, and high infection risk, limit their clinical application. An
alternative solution is processed allogenic and xenogenic bone grafts. Al-
though all the living cells are destroyed during graft processing and stor-
age, these grafts remain associated with the risks of immunoreactions,
disease transmission, and poor osteoconduction capacity. Other tech-
niques, including distraction osteogenesis, bone marrow aspirate, and
growth factors, are commonly used in experimental and clinical condi-
tions for bone defect reconstruction. These methods are associated with
several disadvantages, including the limited osseointegration and revas-
cularization of large bone grafts. Therefore, these problems have resulted
in increased interest in improving functional bone graft solutions for
better patient outcomes.
1.3. Standard Approach and Limitations of Bone Tissue Engineering (BTE)
With the progress of new technologies, regeneration of bone tissue
following tissue engineering principles now represents another strategy
for bone defect reconstruction. BTE aims to regenerate new, cell-driven
bony tissuewith hierarchical organization and anatomical function sim-
ilar to naturally occurring bone tissue. This approach requires the col-
laborative efforts of scientists, engineers, and surgeons. BTE strategies
have relied on two approaches: in vitro or in vivo tissue engineering.
The in vitro BTE strategy attempts to create functional bone grafts by
culturing osteogenic cells on bioactive scaffolds in vitro. In vitro BTE
has observed tremendous growth and evolved to a sophisticated level
in bioreactor design, scaffold engineering, and long-term tissue construct
maintenance (Fig. 1A). However, thismethodology does not consider the
functional elements of the regenerative environment, including im-
mune, nervous, and hormonal systems, which play crucial roles in tissue
regeneration and organ development. Furthermore, diffusion, vasculari-
zation, and neurotization challenges are the major obstacles in BTE. Al-
though in vitro bioreactors have been successfully designed to mimic
the in vivomicroenvironment by precise control of these regeneration-
related parameters (Salehi-Nik et al., 2013), recapitulating the true in
vivo conditions under ex vivo circumstances is difﬁcult. Therefore, after
an in vitro engineered bone graft is transplanted into the body, it lacks
its own vascular and nerve networks to support cell survival and matrixsynthesis and thus must rely on the ingrowth of neo-vascular structures
from its surroundings, resulting in limited long-termoutcomes in clinical
therapeutic studies.
An emerging trend to circumvent these problems is following the in
vivo bioreactor (IVB) principle, which uses the body as a bioreactor to
cultivate the traditional triad (scaffolds, cells, growth factors) and to
leverage the body's own self-regenerative capacity to regenerate new
tissue (Fig. 1B). A key advantage of the IVB strategy is that the body
can offer a constant stream of stem cells to create a regenerative niche
and native signals for tissue growth (Fig. 2). Furthermore, the IVB ap-
proach often bypasses excessive manipulation of cells and growth fac-
tors during ex vivo culture, thus ensuring that the cells retain their
functional properties. Recent preclinical and clinical investigations of
bone graft prefabrication following the IVB principle have shown prom-
ising results and demonstrated efﬁcacy in the reconstruction of large
volume bone defects.
A growing body of work and the signiﬁcant promise of IVB strategies
for bone regeneration havemotivated the preparation of the current re-
view, in which we introduce the concept of bone graft prefabrication
following the IVB principle, discuss different types of IVB strategies,
and summarize the current experimental and clinical experiences in
bone defect reconstruction using prefabricated bone grafts. Finally, we
highlight the bottlenecks of clinical translation of this concept and out-
line future trends in bone graft prefabrication.
2. Bone Graft Prefabrication Following the IVB Principle: Basic
Considerations
2.1. Prefabrication: A Bridge between Reconstructive Surgery and
Regenerative Medicine
Flapprefabrication is oneof themost exciting areas in plastic surgery
because of its bridging role between conventional reconstructive sur-
gery and tissue engineering. Prefabrication is a surgical term that was
ﬁrst introduced by Shen (Yao, 1982) and that describes the implantation
of a vascular pedicle into a new territory, followed by a neovasculariza-
tion period and subsequent tissue transfer based on its implanted pedi-
cle (Fig. 3A). Prefabrication allows any deﬁned tissue volume to be
transferred to any speciﬁed recipient site, greatly expanding the arma-
mentarium of reconstructive options (Xie et al., 2014). Interestingly,
this term seems to have “off-label” uses in the literature. For instance,
by implantation of an avascular construct, such as a three-dimensional
(3D) auricular cartilage construct (von Bomhard et al., 2013) or a trache-
al allograft (Vranckx et al., 2014), into a vascular territory for a period,
the avascular construct would be revascularized and could be trans-
ferred as a composite ﬂap for tissue defect reconstruction (Fig. 3B).
This procedure has also been given the surgical term “prelamination”.
However, the core concept of prefabrication and prelamination is
based on the revascularization phenomenon: from the implanted vascu-
lar pedicle to the avascular receipt territory or from the vascular host
territory to the implanted avascular construct (Pribaz and Fine, 1994;
Yao, 1981). Using the prefabrication or prelamination technique, other
tissue, including a vascularized bone ﬂap (Chen et al., 2007), a piece of
beating cardiac muscle (Morritt et al., 2007), or a functional neo-endo-
crine organ (Borud et al., 1996), can be artiﬁcially regenerated with the
desired size and shape to ﬁt any defect. Gradually, the deﬁnition and
value of prefabrication have been signiﬁcantly expanded in clinical prac-
tice (Wei and Li, 2013). Thus, the current generalized deﬁnition of prefab-
rication should include not only revascularization and prelamination but
also regeneration, which will lead to a new technique for tissue regener-
ation (Fig. 3C).
2.2. Basic Principles of the IVB Strategy
The term “in vivo bioreactor” was ﬁrst coined in 2005 by two inde-
pendent studies (Holt et al., 2005; Stevens et al., 2005) in which the
Fig. 1. Schematic illustration of the BTE paradigm. (A) Classic in vitro BTE paradigm. (B) In vivo BTE paradigm.
(The photograph of a temporomandibular joint-shaped scaffold is adapted from Grayson et al. (2010).)
Fig. 2. Illustration of the role of an IVB.
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to successfully induce new bone formation. To date, the IVB concept has
been applied in a series of experimental and clinical studies to induce
the regeneration of various tissues. In these studies, to take advantage
of the body's intrinsic self-regenerative capability, the traditional triad
elements or a combination thereof are cultivated using the body as a
bioreactor at the damage site or within ectopic sites capable of
supporting neo-tissue formation. After a period of in vivo cultivation,
functional tissues or organs are regenerated and can be used for tissue
defect reconstruction. Although the study models and designs entirely
differ from each other, the basic principles of an IVB strategy are similar:
choose an appropriate anatomical site for providing a regenerative mi-
croenvironment, and seek an optimal combination of the traditional
triad elements to serve as structural and logistical templates for tissue
formation.
The combination of the IVB principle and surgical prefabrication
techniques represents a new strategy for tissue regeneration. The IVB
principle provides a regenerative niche to create new tissue and surgical
prefabrication techniques allow the regenerated tissue to be transferred
as prefabricated ﬂap for optimal reconstruction. Bone graft prefabrica-
tion following the IVB principle can ideally eliminate the previously de-
scribed limitations of in vitro BTE. Speciﬁcally, the in vitro expansion and
seeding of cells can be modiﬁed by chemotaxis of pluripotent stem or
Fig. 3. Schematic concept of ﬂap prefabrication, ﬂap prelamination, and tissue prefabrication. (A) Technological paradigm of traditional ﬂap prefabrication. (B) Technological paradigm of
ﬂap prelamination. (C) Technological paradigm of tissue prefabrication following the IVB principle.
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tem, the biochemical molecular signals can be replaced by autologous
growth factors as well as other supportive stimuli, and a neurovascular
network supplying the regenerated tissue can be recreated in situ,
allowing later transplantation of the vascularized neo-tissue or organoid
to the desired site. All these components can contribute to the in vivo
niche, helping to determine the ultimate functional outcome.
2.3. IVB Types: Basic Characteristics
Anatomically, the IVB is not only a vascular territory but also a regen-
erative niche for vascularization, regeneration, and remodeling of the
prefabricated bone grafts. The most important consideration for an
IVB strategy is the tissue type surrounding the bioreactor, whichmay di-
rectly affect interactions with the implanted construct, the recruitment
of autologous cells, the reestablishment of a neurovascular network, and
the ﬁnal results of bone graft prefabrication. The location of the IVB is
also crucial for the regeneration and clinical application of bone grafts.
Orthotopic prefabrication of bone grafts allows direct reconstruction
of the bone defect without secondary bone graft transfer surgery. How-
ever, in many cases, the bone defect site cannot provide a sufﬁcientregenerative microenvironment because of chronic infection, radiation
treatment, or excessive degeneration. Under such conditions, prefabri-
cation of bone grafts at an ectopic site is an alternative option. An
adequate ectopic site can provide adequate conditions for cellular colo-
nization, vascularization, physical stimulation, and easy access for surgi-
cal operation.
2.3.1. Subcutaneous Pocket
The subcutaneous pocket is the simplest model of all IVB strategies
for bone graft prefabrication and has been widely used in ectopic bone
formation models (Huang et al., 2014, 2015). Only reports that aimed
to regenerate bone grafts following the IVB principle are included in
this review. Generally, the subcutaneous pocket is an artiﬁcially created
space between the superﬁcial and deep subcutaneous fascia, which is a
non-osseous environment. This space provides regenerative cues for
complex bone graft prefabrication. Using this approach, bone grafts
with complex tissue phenotypes and custom-made shapes have been
successfully prefabricated in the laboratory (Lee et al., 2009). Surgically,
themost important considerations for the subcutaneous pocket strategy
are technical. The subcutaneous pocket approach is advantageous as (1)
a wide range of anatomical locations can be chosen, (2) implantation in
47R.-L. Huang et al. / EBioMedicine 12 (2016) 43–54the donor site and transplantation to the recipient site can be performed
easily, and (3) donor site morbidity and complications are minimized.
However, the current available subcutaneous implantation site for
bone formation is a relatively avascular territory without abundant
blood ﬂow in comparison to other IVB strategies. Therefore, subcutane-
ous pockets lack natural osteogenic and angiogenic stem cells, growth
factors, and hormones that are required during bone regeneration.
2.3.2. Muscular Pouch or Flap
Muscle tissue has a rich capillary and nerve network and can be used
as an IVB for bone graft prefabrication. As a model for the IVB strategy,
muscle tissue is usually used to wrap the scaffold in the form of an intra-
muscular pouch or a pedicledﬂap to induce ectopic neurovascularization
and bone regeneration. This strategy was ﬁrst reported in 1991 when
Khouri et al. placed thigh adductor muscle island ﬂaps and allogenic
demineralized bone matrix (DBM) in silicone rubber molds. After a 10-
day in vivo cultivation period, the muscular ﬂaps transformed into can-
cellous bone grafts shaped identically to the mold (Khouri et al., 1991).
Since this technique was ﬁrst reported, it has developed rapidly and
been well investigated in subsequent studies. To date, in addition to nu-
merous experimental studies, at least 4 clinical papers have reported
promising results for bone graft prefabrication using a muscular pouch
or ﬂap as an IVB (Warnke et al., 2004; Heliotis et al., 2006; Mesimäki et
al., 2009; Kokemueller et al., 2010).
One of the most important advantages for the muscular strategy is
that muscle provides plenty of native skeletal progenitor cells that can
be differentiated into bone cells. Therefore, evenwithout the transplan-
tation of exogenous osteoprogenitor/stem cells, regeneration of large
volume bone tissue can be achieved in an intramuscular environment
(Liu et al., 2014). Another critical advantage of this approach is the pres-
ence of bone-formingmolecules that spread out from the site of muscle
injury and lead to natural upregulation of osteogenic signals, including
BMPs, transforming growth factor-beta 1 (TGF-β1), and insulin-like
growth factor 1 (IGF-1) (Scott et al., 2012).
2.3.3. Periosteal Flap
Periosteum is a thin but highly vascularized and innervated tissue
with a bilayer structure: the outer ﬁbrous layer contains ﬁbroblasts
dispersed between collagen ﬁbers and is thought to serve a primarily
structural role, whereas the inner cambium layer consists primarily of
skeletal progenitor cells and osteoblasts that possess a remarkable ca-
pacity to allow appositional bone growth aswell as cortical bonemodel-
ing and remodeling. In light of these ﬁndings, surgeons have harnessed
this osteogenic capacity in bone graft prefabrication research to induce
bone formation. In the periosteal ﬂap strategy, a periosteal ﬂap is used
to wrap the tissue-engineered construct or to cover the chamber
containing the tissue-engineered construct. Therefore, the perioste-
um-construct composite forms an IVB to provide pluripotent cells and
bimolecular signals for the process of bone formation, which ﬁnally re-
sults in a wound-healing response within the space and culminates in
neo-bone formation as opposed to a ﬁbrotic scar. Several signiﬁcant fea-
tures of the periosteal ﬂap indicate that it is an excellent strategy for
bone graft prefabrication. First, the cambium layer of the periosteum
provides a reservoir for periosteum-derived mesenchymal stem cells
(Chang and Knothe, 2012). Second, the periosteum can synthesize
many growth factors, including BMPs, TGF-β1, IGF-1, vascular endothe-
lial growth factor (VEGF), and stromal derived factor 1 (Cuthbert et al.,
2013). Third, implants placed in the periosteum envelope are exposed
to a highly neurovascular environment and to increased blood/nerve-
borne nutrients. Fourth, this strategy of wrapping the implants within
a periosteal envelope utilizes the guided bone regeneration treatment
concept, which has been proven safe and effective in guiding the bone
regeneration process (Dimitriou et al., 2012). However, the periosteal
ﬂap strategy also has limitations. One of the most important consider-
ations is the lack of an adequate donor site to offer a large periosteal
ﬂap for the prefabrication of large or geometry-customized bone grafts.2.3.4. Axial Vascular Bundle (AVB)
Unlike the random blood vessel pattern in the above-mentioned
subcutaneous pockets and tissue ﬂaps, the AVB strategy is an intrinsic
axial osteogenesis and vascularization model for bone graft prefabrica-
tion. In this model, an artery and vein are inserted centrally within a
scaffold to transport progenitor/stemcells, cytokines, oxygen, and nutri-
ents and to removewaste products from the cells, resulting in extensive
vascularization and osteogenesis of the scaffold. The result of the AVB-
based prefabrication strategy is an axial pattern bone graft that can be
transferred to the bone defect site as a pedicled or free ﬂap. Many re-
ports have described the use of superﬁcial inferior epigastric vessels, sa-
phenous vascular bundles, femoral vascular bundles, and perforating
vessels from the thoracodorsal trunk as IVBs to prefabricate bone grafts.
These promising results have demonstrated the feasibility of this strat-
egy for use in clinical patients.
Although the AVB supplies progenitor/stem cells from the whole
body, due to the small contact surface between theAVB and the scaffold,
achieving a well-ossiﬁed and well-vascularized bone graft within a
certain prefabrication period is difﬁcult. An alternative solution is to
envelop the scaffold within an above-mentioned tissue ﬂap, such as a
muscular ﬂap or a periosteal ﬂap. The combined use of the AVB and tis-
sue ﬂap to form an IVB is advantageous due to the utilization of two
well-established bone graft prefabrication strategies. We previously
prefabricated vascularized bone grafts by inserting a saphenous vascu-
lar bundle into a beta tricalcium phosphate (β-TCP) scaffold wrapped
within a localmuscularismembrane (Han andDai, 2013) or a periosteal
ﬂap (Han et al., 2014). The results showed a plentiful capillary network,
chondrocytes, and lamella bones in the regenerated grafts. Another
challenge in clinical translation of the AVB strategy is the lack of donor
AVBs. This strategy requires a long length of artery and vein located at
a superﬁcial site for use as a ﬂap pedicle for distant transfer.
2.3.5. Arteriovenous Loop (AVL)
Inadequate adjacent arterial supply and venous outﬂow due either
to the injury or to preexisting vascular disease may preclude the use
of an AVB as an IVB. In such a case, the AVL can be employed for bone
graft prefabrication. Typically, anAVL is constructed by thedirectmicro-
surgical anastomosis of an artery and a vein or by the interposition of a
venous graft between an artery and a vein to form an arteriovenous ﬁs-
tula. The AVL is then placed inside a chamber containing a scaffold to
create an IVB. A perfused capillary network will sprout from a central
vessel into the surroundings and remodel to generate arterioles, post-
capillary venules, and venules, ﬁnally resulting in accelerated vascular-
ization and new tissue formation (Lokmic et al., 2007). Thismethodwas
ﬁrst described by Erol and Spira, who successfully constructed a
prefabricated skin graft in rats using an AVL between femoral vessels
(Erol and Spira, 1980). Employing the AVL strategy, formation of a sig-
niﬁcant neovascular network and new tissue, such as cartilage tissue
(von Bomhard et al., 2013), cardiac tissue (Morritt et al., 2007), and
muscle tissue (Bach et al., 2006), originating from the arteriovenous
ﬁstula have been described.
The superiority of the AVL strategy over the AVB strategy in terms of
both axial angiogenesis and osteogenesis has been clearly demonstrat-
ed. Compared with the AVB strategy, the AVL strategy showed a greater
potential for producing capillaries and new tissue and was considered
more effective for the development of vascularization and osteogenesis
in bone graft prefabrication (Dong et al., 2012a). Theoretically, three
potential mechanisms are considered responsible for the accelerated
angiogenesis: (1) local inﬂammation due to the surgical trauma on the
vessels promotes the release of inﬂammatory factors and the develop-
ment of the capillary network, (2) elevated vascular ﬂow shear stress
on the venous wall due to arterialization promotes the growth of
collateral vessels and increases the number of microvessels, and (3)
gradient hypoxia within the matrix leads to the upregulation of hypox-
ia-inducible factor 1 and the expression of several angiogenic factors.
Subsequently, prevascularization of the scaffolds helps to recruit,
48 R.-L. Huang et al. / EBioMedicine 12 (2016) 43–54proliferate, and differentiate progenitor/stem cells, consequently opti-
mizing bone formation in the scaffold. However, the osteogenic capacity
of the AVL also depends on the accompanying bioactive scaffold. A
higher extent of vascularization but a lower yield of bone have also
been observed for the AVL strategy due to faster β-TCP scaffold degra-
dation (Wu et al., 2015b). Scaffolds with a slower biodegradation rate,
such as β-TCP/hydroxyapatite (HA) (Eweida et al., 2014) and processed
cancellous bone matrix (Arkudas et al., 2007), continue to be used for
bone graft prefabrication.
In addition, the AVL strategy can be created at any surgical site and
transferred as a free ﬂapusingmicrosurgery techniqueswithout consid-
ering the vascular pedicle length, which greatly expands the clinical ap-
plication potential of this technique. Furthermore, a modiﬁed AVL
strategy in which the arteriovenous ﬁstula is placed in a special porous
chamber, allowing the connection of extrinsic vesselswith intrinsic ves-
sels over time, showed signiﬁcantly increased angiogenesis and bone
regeneration (Weigand et al., 2015). Extrinsic vessels contribute to
faster vascularization and ﬁnally anastomosewith the intrinsic vascula-
ture, reducing the period of bone graft prefabrication and the limitation
of operative interventions using only the AVL strategy. However, this
method remains highly challenging because most load-bearing bone
grafts are not suited to be molded or shaped around the AVL.3. Literature Review
To analyze the current state of the art, we searched the PubMed
Medline databases for articles published between Jan. 1, 1991, and Jan.
1, 2016, using the search terms “in vivo bioreactor”, “in vivo tissue engi-
neering”, “bone tissue engineering”, “bone graft prefabrication”, and
“bone regeneration”. We included 110 publications regarding bone
graft prefabrication following the IVB principle (Fig. 4). We categorized
all the publications into small animal models, large animal models, and
clinical studies to evaluate the safety, efﬁcacy, and cost effectiveness of
the IVB strategies. The studies publishedwithin the last 5 years are sum-
marized in Tables 1–3.Fig. 4. (A) Published articles on bone graft prefabrication following the IVB principle from
Jan. 1, 1991, to Jan. 1, 2016, on PubMed. (B) Break-down of the published articles
according to IVB strategies.3.1. Small Animal Models (Table 1)
In this review, small animal models are deﬁned as mice, rats, and
rabbits. These studies took advantage of small animals because they
are inexpensive to purchase and maintain, because surgeries can easily
be performed on them, and because promising results have been
observed. The ﬁrst study of bone graft prefabrication was performed
in Lewis rats in 1991 by Khouri et al. Although the concept of bone
graft prefabrication following the IVB principle was not clearly elucidat-
ed in that paper, the authors described an effective muscular ﬂap strat-
egy for bone graft prefabrication (Khouri et al., 1991). This landmark
study proposed the “bone transformation” concept at a clinically
available level that matched the current concept of bone graft prefabri-
cation following the IVB principle. Subsequently, bone grafts with geo-
metric shapes and even composite tissue layers were successfully
prefabricated in small animal models using different IVB strategies.
However, due to the size of small animals, testing the diffusion efﬁcacy
and osteogenic and angiogenic capacities of the IVBs is difﬁcult. Further-
more, while validating a new concept or technique in small animal
models is feasible, the limitations to the prefabrication of clinically rele-
vant bone grafts with large dimensions and precise shapes in small an-
imal models have always been a challenge to the successful translation
of experimental achievements to clinical applications.
3.2. Large Animal Models (Table 2)
After successful results were reported for small animalmodels, large
animalmodels, including sheep,mini pigs, dogs, andmonkeys,were de-
veloped to verify the practicability of the IVB strategies closer to real
clinical situations. Latissimus dorsi muscle, rib periosteum, and AVL
are the most commonly used IVB strategies in these models. Since
1999, Terheyden and his team have reported a series of studies on
bone graft prefabrication using the latissimus dorsi muscle as an IVB
in mini pigs (Warnke et al., 2006a; Terheyden et al., 1999; Terheyden
et al., 2001a; Terheyden et al., 2001b; Terheyden et al., 2004). In light
of the promising results in these studies, Warnke et al. translated this
strategy into a clinical patient (Warnke et al., 2004; Warnke et al.,
2006b). Another extensively studied strategy in large animals is the
AVLmodel, which has been validated in small animalmodels. By scaling
up the AVL model, clinically approved, mechanically stable bone grafts
with a signiﬁcant volume were prefabricated in sheep or goat models,
implying the feasibility of clinical translation in future work (Beier et
al., 2011; Beier et al., 2010; Boos et al., 2013). Using the AVL strategy,
Eweida et al. improved the commonly used ectopic prefabrication ap-
proach to the in situ prefabrication approach and tested its clinical trans-
lation possibility in goats (Eweida et al., 2011; Eweida et al., 2012;
Eweida et al., 2014). The results showed that the AVL strategy induced
better vascularization at the central regions and permitted more efﬁ-
cient bone regeneration. This in situ bone graft prefabrication strategy
that used the AVL strategy was also successfully translated into clinical
patients with critical-sized long bone defects (Horch et al., 2014).
Although, large animal studies have shown exciting results in
prefabricating vascularized bone grafts with complex geometry and
clinically relevant sizes, further efforts are required to optimize the pre-
fabrication time, implantation location, and biomaterial application.
3.3. Clinical Cases (Table 3)
To date, only 7 scientiﬁc papers have reported 8 cases of bone defect
reconstruction following the IVB principle in humans. The groundbreak-
ing case was performed in 1990 but reported in 1999 by Orringer et al.
(1999). A female patient who suffered a subtotal mandibular defect
underwent a bone graft prefabrication procedure for mandibular
and total lower lip reconstruction. In this case, a mandibular-shaped
osteocutaneousﬂapwas successfully prefabricated using a thin scapular
fasciocutaneous ﬂap as an IVB and cancellous bone grafts from the iliac
Table 1
Recent bone graft prefabrication studies in small animal models.
Reference/year Animal model IVB Scaffold Seed cells Growth factor
Ersoy et al., 2015 Rat Periosteal ﬂap Bioactive glass or HA within a
Gore-Tex pocket
None None
Patel et al., 2015a Mouse Subcutaneous pocket PCL None BMP-2
Patel et al., 2015b Mouse Subcutaneous pocket PCL None BMP-2 and EPO
Buehrer et al., 2015 Rat AVL between FVs HA, β-TCP, and ﬁbrin gel MSCs BMP-2
Sathy et al., 2015a;
Sathy et al., 2015b
Mouse Subcutaneous pocket PCL, HA, and gelatin MSCs None
Wu et al., 2015a Mouse Subcutaneous pocket β-TCP and CHA BMSCs None
Han et al., 2014 Rabbit Tibial periosteal ﬂap combined
with AVB from SVs
β-TCP BMSCs None
Han and Dai, 2013 Rabbit Muscular membrane combined
with AVB from SVs
β-TCP BMP-2-transfected BMSCs None
Nakamura et al., 2013 Rat AVB from SVs Bone allografts None BMP-2
Rodrigues et al., 2013 Rat AVB from SIEVs Deep-frozen bone or
lyophilized-demineralized bone
None None
Yang et al., 2013 Rat AVB from SIEVs nHA-PA 66 Endothelial induced ADSCs None
Cai et al., 2013 Rabbit AVB from FVs Fibrin matrix within an inion
membrane tube
None BMP-2
Scotti et al., 2013 Mouse Subcutaneous pocket Type I collagen mesh Chondrogenic induced MSCs None
Koca et al., 2012 Rabbit AVB or subcutaneous pocket Human bone allografts None None
Dong et al., 2012c Rabbit AVB from SVs β-TCP within a titanium cage BMSCs None
Sever et al., 2012 Rat AVB from SIEVs PCHC BMSCs VEGF
Dong et al., 2012b Rabbit AVB from SVs β-TCP within a titanium cage BMSCs and PRP None
Dong et al., 2012a Rabbit AVL between FVs Natural coral blocks wrapped
with an ePTFE membrane
None None
Arkudas et al., 2012 Rat AVL between FVs HA/β-TCP/ﬁbrin matrix None None
Rath et al., 2011 Rat AVL between facial vessels PLDLLA-TCP-PCL Osteoblasts BMP-2
Kloeters et al., 2011 Rabbit AVB from inguinal vessels PBCB Osteogenic induced ADSCs None
Farrell et al., 2011 Mouse Subcutaneous pocket Collagen-GAG scaffolds Osteogenic or chondrogenic
induced hMSCs
None
Binderman et al., 2011 Rat Subcutaneous pocket DBM None None
Sever et al., 2010 Rat AVB from SIEVs HA BMSCs None
Okuda et al., 2010 Rat Fascia ﬂap pedicled on SIEVs β-TCP Osteogenic induced ADSCs None
Yachouh et al., 2010 Rabbit Femur periosteal ﬂap pedicled on
the descending artery of the knee
Irradiated bone fragment None None
Wang et al., 2010 Rabbit AVB from FVs β-TCP MSCs None
Dong et al., 2010 Rabbit AVL between FVs Natural coral blocks wrapped
with an ePTFE membrane
None None
Chang et al., 2010 Rabbit AVB from FVs HA and collagen gel breads
wrapped with an ePTFE membrane
MSCs None
Kamei et al., 2010 Rabbit Omentum ﬂap wrapped periosteum
free graft
None None None
Arkudas et al., 2010 Rat AVL between FVs HA/β-TCP granula None VEGF165 and bFGF
ADSC, adipose-derived stem cells; AVB, axial vascular bundle; AVL, arteriovenous loop; bFGF, basic ﬁbroblast growth factor; BMP-2, bonemorphogenetic protein 2; BMSCs, bonemarrow
mesenchymal stem cells; β-TCP, beta-tricalcium phosphate; CHA, coralline hydroxyapatite; DBM, demineralized bonematrix; ePTFE, expanded-polytetraﬂuoroethylene; EPO, erythropoi-
etin; FVs: femoral vessels; HA, hydroxyapatite ceramic; MSCs, mesenchymal stem cells; nHA-PA 66, nano-hydroxyapatite-polyamide 66; PBCB, processed bovine cancellous bone; PCHC,
porous calcium hydroxyapatite ceramic; PCL, poly-ε-caprolactone; PLDLLA, poly(L-lactide-co-D,L-lactide); SIEVs: superﬁcial inferior epigastric vessels; SVs: saphenous vessels; VEGF, vas-
cular endothelial growth factor.
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magnetic resonance imaging revealed excellent ossiﬁcation in the ﬂap
during the prefabrication phase, indicating the capacity of new bone re-
generation in the fasciocutaneous ﬂap. This work provided important
inspiration showing that prefabricating a clinically-relevant bone graft
following the IVB principle was clinically possible.
The most commonly used strategy in clinical cases is the muscular
pouch or ﬂap. In total, 4 of the 7 publications used this strategy and
yielded promising results. Following their initial successes using the
latissimus dorsi muscle as an IVB in pigs, Warnke et al. reported the
growth and transplantation of a vascularized mandible in a patient
with an extended mandibular discontinuity defect (Warnke et al.,
2004; Warnke et al., 2006b). In this case, an artiﬁcially created bone
ﬂap was regenerated in the latissimus dorsi muscle by implanting a
well-designed scaffold. After 7 weeks, the muscle-bone ﬂap pedicled
on the thoracodorsal vessels was harvested and transferred to ﬁll the
mandibular defect. Bone scintigraphy showed active bone formation
and remodeling during the prefabrication phase and after transplanta-
tion, indicating undisturbed vascular perfusion as well as survival of
the induced bone cells. This patient gained both functional and esthetic
mandibular reconstruction. This landmark case offered an innovativemethod for designing customized bone grafts and avoiding the creation
of secondary bone defects. Inspirited by these promising results,
researchers continued to improve the muscle strategy in clinical
application. Heliotis et al. successfully transformed a HA/OP-1 compos-
ite construct into a vascularized bone graft by implanting this construct
into the pectoralis major muscle in a female patient with a
hemimandibular defect (Heliotis et al., 2006). This case is notable for
the successful prefabrication of a bone ﬂap without the additional use
of autologous elements. The next case presented by Mesimäki et al.
was a male patient who underwent hemimaxillectomy (Mesimäki et
al., 2009). A custom-made bone ﬂap was prefabricated by implanting
a preformed titanium cage ﬁlled with ADSCs, β-TCP, and BMP-2 into
the rectus abdominis muscle. After 8 months, the prefabricated bone
ﬂap was placed into the maxillary defect and ﬁnally osseointegrated
to the host maxillary bone without any adverse events. This clinical
case is the ﬁrst in which ectopic bone formation was produced using
good manufacturing practice level ADSCs. Kokemueller et al. improved
the muscular strategy by inserting an AVB from the thoracodorsal
trunk into the β-TCP cylinders before intramuscular implantation
(Kokemueller et al., 2010). Before clinical translation, the AVB-muscle
strategy showed excellent angiogenesis, ossiﬁcation, and ceramic
Table 2
Recent bone graft prefabrication studies in large animal models.
Reference/year Animal model IVB Scaffold Seed cells Growth factor
Spalthoff et al., 2015 Sheep Muscular pouch in LDM combined
with AVB from thoracodorsal trunk
β-TCP cylinder and MBG BMA None
Tatara et al., 2015 Sheep Cambium layer of rib periosteum Combination of MBG, HA, and β-TCP
within a PMMA chamber
None None
Zhou et al., 2010;
Zhou et al., 2015
Monkey Muscular pouch in LDM DFBA or CHA None BMP-2
Weigand et al., 2015 Sheep AVL between SVs NanoBone (HA) block Autologous blood None
Wu et al., 2015b Dog AVL between SVs or AVB from SVs β-TCP cylinder BMSCs None
Eweida et al., 2011;
Eweida et al., 2012;
Eweida et al., 2014
Goat AVL between facial vessels 60% HA combined 40% β-TCP PRP BMP-2
Liu et al., 2014 Pig Muscular pouch in LDM NBBM or a mixture of NBBM and
autogenous bone particles within
a titanium cage
None BMP-7 and
VEGF
Kokemüller et al., 2014 Sheep Muscular pouch in LDM combined
with AVB from thoracodorsal trunk
β-TCP and unmodiﬁed osteogenic
material from the iliac crest within
a titanium cage
BMA, NCC,
or BMSCs
None
Zhi et al., 2014 Dog Abdominal cavities or dorsal muscles HA None None
Chen et al., 2014 Dog Muscular pouch in LDM DBM BMSCs or PRP None
Tsao et al., 2014 Dog Omentum ﬂap wrapped
periosteum-free graft
None None ADSCs
Boos et al., 2013 Sheep AVL between SVs β-TCP-HA granules BMSCs BMP-2
Bigham-Sadegh et al., 2013 Dog Omentum ﬂap wrapped
periosteum-free graft
None None None
Beier et al., 2011 Sheep AVL between greater SVs PBCB construct None None
Kokemueller et al., 2010 Sheep Muscular pouch in LDM combined with AVB
from thoracodorsal trunk
β-TCP BMA None
Runyan et al., 2010 Pig Periosteal envelope or rectus abdominis
muscle with insertion of AVB from SIEVs
Processed allogeneic
hemimandible
ADSCs BMP-2
Beier et al., 2010 Sheep AVL between SVs HA and β-TCP None None
ADSC, adipose-derived stem cells; AVB, axial vascular bundle; AVL, arteriovenous loop; BMA, bonemarrow aspirate; BMP-2, bone morphogenetic protein 2; BMP-7, bone morphogenetic
protein 7; BMSCs, bone marrow mesenchymal stem cells; β-TCP, beta-tricalcium phosphate; CHA, coralline hydroxyapatite; DBM, demineralized bone matrix; DFBA, demineralized
freeze-dried bone allograft; HA, hydroxyapatite ceramic; LDM: latissimus dorsi muscle; MBG, morcellized bone graft; NCC, nucleated cell concentrate; PBCB, processed bovine cancellous
bone; PMMA, poly(methyl methacrylate); PRP, platelet-rich plasma; SIEVs: superﬁcial inferior epigastric vessels; SVs: saphenous vessels; VEGF, vascular endothelial growth factor.
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in sheep. These results encouraged the authors to forgo the additional
use of growth factors and to translate this strategy into patients.
The periosteal ﬂap strategy and AVL strategy have also been applied
in clinical cases. To augment mandible height during reconstruction,
Cheng et al. ﬁxed a chamber ﬁlled with morcellized autografts against
the cambium layer of the rib periosteum for 8 weeks (Cheng et al.,
2006). Solid bone graft extending from the periosteumwas transferred
to augment the mandible height. The results revealed well-retainedTable 3
Bone graft prefabrication studies in clinical cases.
Reference/year Defect treated
No. of
patients IVB
Prefabr
time
Horch et al., 2014 Tibial defect 1 AVL between popliteal
vessels
N/A (in
prefabr
Radialis defect 1 AVL between radial artery
and cephalic vein
Kokemueller
et al., 2010
Mandibular defect 1 Muscular pouch in LDM
combined with AVB from
thoracodorsal trunk
Over 6
Mesimäki et al., 2009 Maxillary defect 1 Muscular pouch in rectus
abdominis muscle
8 mo
Cheng et al., 2006 Mandibular defect 1 Cambium layer of iliac
periosteum
8 wk
Heliotis et al., 2006 Mandibular defect 1 Muscular pouch in
pectoralis major muscle
6.5 mo
Warnke et al., 2004;
Warnke et al.,
2006b
Mandibular defect 1 Muscular pouch in LDM 7 wk
Orringer et al., 1999 Mandibular defect 1 Thin scapular
fasciocutaneous ﬂap
4 mo
ADSC, adipose-derived stem cells; AVB, axial vascular bundle; AVL, arteriovenous loop; BMA, bo
protein 7; β-TCP, beta-tricalcium phosphate; LDM: latissimus dorsi muscle; PMMA, poly(methosseointegrated dental implants in the prefabricated bone graft until
16 months later. This case demonstrated the osteogenic and angiogenic
capacity of the periosteal ﬂap for clinical bone graft prefabrication. Re-
cently, Horch et al. reported their successful experience with long
bone defect reconstruction using the AVL strategy (Horch et al., 2014).
For osseous reconstruction, critical-sized bone defects were ﬁlled with
AVLs andmorcellized autografts or β-TCP/HA. Long-term follow-up ex-
aminations showed functional osseous reconstruction without any
osteosynthetic ﬁxation. The salient results of the study were as follows:ication
Scaffold
Seed
cells
Growth
factor
Outcome and
follow-up time
situ
ication)
Iliac crest autografts None None N/A; 5.5 years
β-TCP and HA BMA None N/A; 32 mo
mo β-TCP and iliac
crest autografts
BMA None N/A; 12 mo
β-TCP within a
titanium cage
ADSCs BMP-2 Osseointegrated without
adverse events; 12 mo
Iliac crest autografts
within a PMMA
chamber
None None Increased mandible height;
died of unrelated
cancer after 16 mo
HA None BMP-7 Infection and necrosis;
5 mo
BioOsss blocks within a
titanium cage
BMA BMP-7 Infection and revision;
died of cardiac arrest after
15 mo
Iliac crest autografts
within a
Dacron-polyurethane cage
None BMP N/A; died of recurrence
after 2 years
nemarrow aspirate; BMP-2, bone morphogenetic protein 2; BMP-7, bone morphogenetic
yl methacrylate).
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the functional reconstruction of large bone defects of extremities at me-
chanical loading sites, and 2) this strategy avoided the creation of signif-
icant donor-site defects and second operations. However, bone defects
caused by tumor sectioning, severe trauma, chronic infection or under-
going radiation treatments are unsuitable for this strategy due to the
impaired regenerative microenvironment in the surrounding tissue.
4. Discussion: Future Trends and Challenges
4.1. Is the In VitroManipulation of Cells, Growth Factors, and even Scaffolds
still Needed?
In the traditional BTE paradigm, seed cells, growth factors, and
bioscaffolds are essential elements for bone regeneration. However, in
vitro manipulation of these elements limits clinical translation due to
the diffusional challenge, insufﬁcient vascularization, and seed cell sur-
vival. Following the IVB principle, the seed cells and growth factors can
be supplied by the surrounding microenvironment or even the entire
body. Lee et al. reported a proof-of-concept study, a TGF-β3 spatially
embedded scaffold was used for homing endogenous cells to the scaf-
fold and inducing differentiation of these cells to regenerate articular
cartilage (Lee et al., 2010). In addition, several researchers have intro-
duced their successful experiences in new bone regeneration achieved
by only a scaffold-based in vivo bioreactor without exogenous cells
and growth factors (Stevens et al., 2005; Gao et al., 2016). These studies
revealed the possibility of using the human body as a living bioreactor
for growth and transplant of complex tissue or organwithout cell trans-
plantation and growth factor administration.
To date, the bioscaffold seemed to be an indispensable component of
bone graft prefabrication. However, a breakthrough was observed in
two promising studies in which bone formation occurred in an IVB
consisting of a periosteal-free graft and an omentum ﬂap without
bioscaffolds, seed cells, and growth factors (Kamei et al., 2010;
Bigham-Sadegh et al., 2013). Furthermore, numerous studies have dem-
onstrated that the periosteum has the capacity to regenerate osseous-
like tissue at ectopic sites without themanipulation of these exogenous
elements (Chen et al., 2009). Similarly, heterotopic ossiﬁcation, a path-
ophysiological phenomenon of ectopic bone formation, actually shows
the body's bone regeneration capacity without these elements (Alﬁeri
et al., 2012). Therefore, the regeneration of a large volume of bony tissue
in vivo using a scaffold-free strategymay be feasible but requires consid-
erable further development.
Theoretically, an ideal IVB strategy minimizes the use of exogenous
scaffolds, seed cells, and growth factors, although many studies still
use these elements to enhance bone regeneration (Huang et al., 2016).
Current studies have focused on the local microenvironment andFig. 5. Further trends of bone defect reconstsurgical techniques, such as searching for an adequate implantation
site to maximize the body's own self-regenerative capacity, optimizing
the prefabrication time to achieve a ﬁne balance between bone regener-
ation and remodeling, and stimulating the route of differentiation un-
dertaken by osteogenic cells (Fig. 5).
4.2. Is Current Evidence Adequate for Clinical Translation?
Although the experimental evidence is well established and the pre-
liminary results fromclinical studies are encouraging, several points still
prevent the safe and widespread application of the IVB principle for
bone graft prefabrication in humans. Functional reconstruction of
bone defects requires the regenerated bonegrafts to possessmechanical
strength,microstructure, and function as similar to native bone tissue as
possible (Guilak and Baaijens, 2014). However, ectopically regenerated
bone grafts remain hardly equivalent to the native bone tissue in histo-
logical structure. For instance, only 17% of the bone graft prefabricated
in Heliotis' clinical case was bone tissue, while the remaining tissue
was 37% HA and 46% ﬁbrovascular tissue. Finally, insufﬁcient soft and
bony tissue and highHA content in the prefabricated bone graft resulted
in necrosis of the bone ﬂap (Heliotis et al., 2006). Furthermore, the
healing potential in humans differs from that in animals and occurs
with various speeds in different bones. Therefore, the prefabrication
time and location of different IVB strategies have not yet been deﬁned
in humans. In addition, bone defects in humansmaybemore complicat-
ed in terms of precise geometry and tissue phenotype than that artiﬁ-
cially created in animal models. Although anatomically shaped bone
grafts with high ﬁdelity and corresponding tissue phenotypes have
been artiﬁcially regenerated in animals, additional evidence is required
regarding continued bone growth and remodeling of the transferred
bone graft, osseointegration with the host bone tissue, and long-term
follow-up of functional recovery.
Anothermajor issue affecting clinical translation is that the IVB strat-
egies for bone defect reconstruction seem to bemore complex than the
current clinically adopted approaches. Patientsmay needmultiple oper-
ations to achieve predictable outcomes. Furthermore, a perfect surgical
schedule, good overall health conditions, and sound cooperation be-
tween the patient and surgeons are required. Extensive efforts should
be devoted to simplifying the surgical procedure and to improving the
cost effectiveness of this method.
4.3. Is it Feasible to Regenerate Complex Tissues, even Whole Organs, Fol-
lowing the IVB Principle?
Recent results in bone graft prefabrication have offered a potential
solution to functionally replace complex tissues and whole organs fol-
lowing the IVB principle. This task becomes more complicated whenruction using prefabricated bone grafts.
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ganization of heterogeneous tissues. Successful proof of the IVB
principle has been shown for complex tissues such as the trachea
(Tsao et al., 2014), full-thickness skin (Eriksson and Vranckx,
2004), bladder (Baumert et al., 2007b), esophagus (Badylak et al.,
2011), and skeletal muscle (Bitto et al., 2013); and for organs such as
the liver (Zhao et al., 2010), heart (Ott et al., 2008), and lung (Wu et
al., 2013). However, the unmet clinical demands in these areas and
the barriers to clinical translation in existing demonstrations are well
known.
Continued challenges for prefabrication of functional complex
tissues or organs will focus on solving the following issues: an ade-
quate IVB strategy to provide a correct regenerative microenviron-
ment, and a sophisticated bioactive scaffold for maintaining tissue
microarchitecture and providing biological signals. Several studies
have introduced IVB strategies for the initial regeneration of complex
tissue. Choi et al. used the omentum of adult rats to cultivate a tubular
scaffold seeded with full-thickness plugs of intestine (Choi et al.,
1998). These organoid units became vascularized and formed a cyst
that histologically resembled the small bowel. Thismodel of in vivomat-
uration using the omentum as an IVB also enabled the generation of a
mature neoureter composed of a well-differentiated multilayered
urothelium (Baumert et al., 2007a; Baumert et al., 2007b). Additionally,
recent advances in the tissue decellularization technique (Arenas-
Herrera et al., 2013) have established a foundation for the functional re-
placement of whole organs with complex tissues and microstructures.
The technique removes cells from allogeneic or xenogeneic whole
organs but maintains their functional architecture to produce an off-
the-shelf 3D organ scaffold. The decellularized organ scaffold then
serves as an inductive biological template around which the recipient
rebuilds functional tissue through the recruitment of endogenous cells
following the IVB principle (Badylak et al., 2012). This impressive feat
has been emulated by successful whole large organ reengineering, in-
cluding the lung (Petersen et al., 2010), liver (Uygun et al., 2010), kid-
ney (Caralt et al., 2015), and limb (Jank et al., 2015). Another key
advantage of the decellularized organ is the ready availability of an in-
tact vascular network that can be connected to the recipient's vascular
system by a combination of IVB strategies such as AVB and AVL.We be-
lieve the current challenges of complex tissue or whole organ prefabri-
cation will be solved in the future by following the IVB principle and
employing other technological advances.5. Conclusion
Comprehensively, these initial results demonstrated that the IVB
strategy can be considered a highly promising approach for bone graft
prefabrication and subsequent bone defect reconstruction. Although
limited success has been observed in clinical cases, this strategy offers
a tremendous advantage over the traditional BTE approaches and ad-
dresses several signiﬁcant bottlenecks in clinical translation of BTE. Nev-
ertheless, research in thisﬁeld is ongoing,with evidence beingprimarily
gained from preclinical studies. Before universal clinical application can
be recommended, future research should aim to develop a simpliﬁed
but effective approach for bone graft prefabrication and translate it to
clinical use as rapidly and as safely as possible.Acknowledgments
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